摘要
脑梗死的病死率及致残率高，给患者和家庭造成了极大的危害。早期再灌注治疗能显著改善急性脑卒中患者的预后。研究表明，依靠病理生理窗而不是单纯的时间窗来选择患者，将更能使脑卒中患者受益。联合动静脉溶栓使血管再通是可行的，并且相对比较安全。rt＋PA是目前唯一被美国FDA批准用于治疗急性缺血性脑卒中的溶栓药物。颅内出血是溶栓治疗最严重的并发症之一。
Stroke carries a severe toll in terms of loss of life and disability for patients and their families.Early reperfusion can dramatically change the outcome of acute stroke patients.Recent and ongoing trials demonstrate the benefit of treating acute stroke patients depending on tissue of risk of infarction rather than timing of onset.A combined intravenous（IV）and intra-arterial（lA）approach to recanalization is feasible and may have comparable safety.The US Food and Drug Administration approved rt-PA the only drug for stroke thrombolysis.lntracerebral haemorrhage still represents the most feared complication of thrombolysis.
出处
《中国中医药现代远程教育》
2010年第17期273-274,共2页
Chinese Medicine Modern Distance Education of China
关键词
脑梗死
溶栓治疗
时间窗
溶栓药物
cerebral infarction
Thrombolysis
Time window： Thrombolytic agents
